Drug Importer Debarred 5 Years Over Unapproved Goods.
Published Date: 3/13/2025
Notice
Summary
Alnashir Alibhai Punjani is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving unapproved drugs. He didn’t respond to the FDA’s notice, so the ban starts on March 13, 2025. Punjani can apply to end the ban anytime, but must follow strict rules to keep personal info private.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
5‑Year Ban on Importing Drugs
Alnashir Alibhai Punjani is debarred for 5 years from importing or offering for import any drug into the United States, effective March 13, 2025. The debarment follows his June 18, 2024 conviction for conspiracy to deliver and introduce unapproved drugs and was imposed under the Federal Food, Drug, and Cosmetic Act.
How to Apply to End Debarment; Privacy Rules
Mr. Punjani may apply at any time to terminate the debarment by submitting an application to docket FDA-2024-N-3314. Electronic applications submitted to https://www.regulations.gov (including attachments) will be posted publicly unchanged, so confidential information should not be included there; to submit confidential information, an applicant must file a written/paper submission with two copies (one marked confidential containing the full information and one redacted copy for public posting) to the Dockets Management Staff at the address provided.
Helping Him Import Is Prohibited
As of March 13, 2025, importing or offering for import any drug by, with the assistance of, or at the direction of Mr. Punjani is a prohibited act under section 301(cc) of the FD&C Act. Businesses or individuals that would assist him in importing drugs would be engaging in a prohibited act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-04028, Harpreet Singh: Final Debarment Order
Harpreet Singh is banned for 10 years from importing any drugs into the U.S. because he was convicted of serious crimes like drug trafficking and fraud. He didn’t respond to the FDA’s notice, so the ban starts on March 13, 2025. Singh can apply to end this ban anytime, but it won’t be easy or quick.
Next: 2025-04030, Jonathan Corbett Cosie: Final Debarment Order
Jonathan Corbett Cosie is banned for 10 years from importing any drugs into the U.S. because he was convicted of selling fake or mislabeled drugs to trick people. He didn’t respond to the FDA’s notice, so the ban started on March 13, 2025. He can apply to end the ban anytime, but must follow special rules to keep personal info private.